508 citations
,
June 2009 in “Current drug metabolism” This review details the skin and hematological toxicities of tyrosine kinase inhibitors like erlotinib, gefitinib, and imatinib, and highlights ongoing concerns about cardiac toxicity, reporting no new clinical findings.
25 citations
,
January 2011 in “Annals of Dermatology” This case report documents a 61-year-old woman treated with erlotinib who experienced the rare side effect of cicatricial alopecia.
12 citations
,
November 2006 in “Journal of thoracic oncology” This case report describes a patient with non-small cell lung cancer who experienced trichomegaly (excessive eyelash growth) as a side effect of erlotinib treatment without developing typical skin rash.
1 citations
,
April 2025 in “Clinical Cosmetic and Investigational Dermatology” This study reports two cases of erlotinib-induced erosive pustular dermatosis of the scalp in patients with non-small cell lung cancer, emphasizing the need for dermatological monitoring during EGFR inhibitor therapy.
April 2023 in “Cancer Research” This study demonstrated that human plucked hairs can be used as a valuable biomarker to evaluate the pharmacodynamic responses of various chemotherapy agents ex vivo, supporting their potential use for assessing oncology drug target engagement prior to clinical studies.